EP1090630A1 — Skin normalizing agents
Assigned to Soken Co Ltd · Expires 2001-04-11 · 25y expired
What this patent protects
The present invention relates to a skin conditioner comprising the compound represented by the general formula: (wherein, the symbols are the same as those defined in the text). Examples of active ingredients of the present invention include L-arginine and ethanolamine. These a…
USPTO Abstract
The present invention relates to a skin conditioner comprising the compound represented by the general formula: (wherein, the symbols are the same as those defined in the text). Examples of active ingredients of the present invention include L-arginine and ethanolamine. These active ingredients can be acquired as chemical synthesis products, or they may also be acquired in the form of natural substances. Preferable Examples of natural substances include substances containing L-arginine and/or ethanolamine obtained from rice. The skin conditioner as claimed in the present invention demonstrates remarkable effectiveness as an agent for the prevention and treatment of atopic dermatitis and as a skin moisture retention agent.
Drugs covered by this patent
- Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.